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Abstract
Heparin, a sulfated polysaccharide belonging to the glycosaminogly-
can family, hasbeenwidelyusedas ananticoagulantdrug fordecades
and remains the most commonly used parenteral anticoagulant in
adults and children. However, heparin has important clinical limi-
tations and is derived from animal sources which pose significant
safety and supply problems. The ever growing shortage of the raw
material for heparin manufacturing may become a very significant
issue in the future. These global limitations have prompted much
research, especially following the recent well-publicized contami-
nation scandal, into the development of alternative anticoagulants
derived from non-animal and/or totally synthetic sources that mimic
the structural features and properties of heparin. Such compounds,
termed heparin mimetics, are also needed as anticoagulant mate-
rials for use in biomedical applications (e.g., stents, grafts, implants
etc.). This review encompasses the development of heparinmimetics
of various structural classes, including synthetic polymers and non-
carbohydrate small molecules as well as sulfated oligo- and polysac-
charides, and fondaparinux derivatives and conjugates, with a focus
on developments in the past 10 years.
K EYWORDS
anticoagulants, glycopolymers, heparin, heparin mimetics, sulfated
oligosaccharides
1 INTRODUCTION
At present, globally, a large number of people are affected with different types of cardiovascular diseases (CVDs), that
is, myocardial infarction (heart attack), stroke, arterial thrombosis and venous thromboembolism (deep vein thrombo-
sis and pulmonary embolism), where the underlying etiology behind these life threatening diseases is the formation
of thrombus (accumulation of aggregated platelets and cross-linked insoluble fibrin).1–3 According to a 2017 WHO
report, CVD is the leading cause of mortality throughout the world accounting for 17.7 million deaths in 2015, and
equivalent to 31%of all deaths.4 Some of themost important treatment options for these life-threatening diseases are
basedonunfractionatedheparin (UFH), lowmolecularweight heparins (LMWH), and the synthetic ultra-lowmolecular
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weight heparin (ULMWH) pentasaccharide, that is, fondaparinux (1, Figure 3), see Table 1. Among these, UFHwhich is
a sulfated polysaccharide (average molecular weight [MW] of most commercial preparations ∼12–30 kDa) has been
in use for decades and offers advantages such as rapid onset of action after intravenous administration, reversibility,
widespread availability, and lowcost.However,UFH is associatedwith serious complications such as bleeding, heparin-
induced thrombocytopenia (which can be fatal), osteoporosis (frequently in females), hypoaldosteronism, heparin-
induced skin necrosis, and variable dose response in different patients, requiring specialmonitoring.5–9 A serious event
took place in 2007/8 when more than 200 patients died after receiving UFH and hundreds were reported to have
serious adverse effects due to contamination; specifically from adulteration of the UFH preparation with oversulfated
chondroitin sulfate (CS).10,14 UFH is obtained from animal tissue (porcine, or occasionally bovine, intestinal mucosa)
and so there is potential for contamination from viruses. In addition, UFH has a very short half-life (less than 1 hr), and
only approximately one-third of the administered dose elicits a therapeutic response.11 Moreover, after complex for-
mationwith antithrombin (AT), heparin cannot inhibit the function of coagulation factors Factor Xa (FXa) and thrombin
(FIIa) when they are bound to platelets and fibrin, respectively.12 Therefore, LMWHs (averageMW∼3.5–6 kDa), were
developed to provide some advantages over UFH, for example, increased half-life, improved bioavailability.13 There is
also the additional advantage of no additional monitoring required following LMWH administration, so that patients
do not need to be hospitalized. However, LMWHs also have some limitations such as functional irreversibility and a
dependence on UFH as the starting material.14 On the other hand, synthetic fondaparinux (1) became commercially
available in 2001 and is frequently prescribed despite the high cost due to its complex synthesis. All of these limita-
tions associated with heparin and its derivatives have motivated the development of alternative anticoagulants with
improved properties. This review focuses on different approaches for the development of heparinmimetics as alterna-
tive anticoagulants. For thepurposesof this reviewwedefineheparinmimetics as compounds thatmimic the structural
features of heparin (principally negatively charged sulfo groups) and therefore its properties.
2 BLOOD COAGULATION
Based on the waterfall model first proposed by Macfarlane in 1964, the zymogen Factor X (FX) is activated to FXa
through two independent pathways, namely the intrinsic and extrinsic pathways.2,15 The ultimate goal is activation of
prothrombin (also known as FII and secreted from platelets) into active thrombin (FIIa), which further stimulates the
generation of abundant fibrin from fibrinogen to form a stable clot. However, recent cell-based coagulation studies
convey that coagulation takes place in three overlapping steps, namely initiation, amplification, and propagation.16,17
During initiation, at the site of vascular disruption, a complex is formed between Factor VIIa (FVIIa) and subendothelial
tissue factor, which activates both Factor IX (FIX) and FX; the complex also generates a small amount of thrombin to
form fibrin via activation of fibrinogen. During amplification, thrombin activates platelets, Factor V (FV), Factor VIII
(FVIII), and Factor XI (FXI). FIXa forms a complex (intrinsic "tenase" complex) with FVIIIa (FIXa:FVIIIa), activating a
sufficient amount of FX into FXa to form a prothrombinase complex with FVa (FXa:FVa).17 This complex generates a
large amount of thrombin to convert fibrinogen into fibrin and to form a clot which becomes stable once Factor XIII
forms crosslinks across fibrin strands.
3 SOURCES, CHEMISTRY AND ANTICOAGULANT ACTIVITY OF UFH,
LMWH, AND ULMWH
Heparin and specificallyUFH is prepared by extraction fromanimal tissue,mostly porcine intestinalmucosa.18 All hep-
arin preparations are linear polymerswith a number averageMW(Mn) of 12 to 16 kDa and aweight averageMW(Mw)
of 17 to 20 kDa, and thus a polydispersity (Mw/Mn) of about 1.3–1.4.19 Themanufacturing processes for heparin have
NAHAIN ET AL. 3
T
A
B
L
E
1
Su
m
m
ar
y
o
ft
h
e
p
ro
p
er
ti
es
o
fU
F
H
,L
M
W
H
,a
n
d
U
LM
W
H
(f
o
n
d
ap
ar
in
u
x)
M
W
(k
D
a)
A
n
ti
co
ag
u
la
n
t
ac
ti
vi
ty
H
al
f-
lif
e
(h
r)
P
ro
d
u
ct
io
n
P
ro
d
u
ct
io
n
co
n
ce
rn
s
A
d
m
in
is
tr
at
io
n
A
d
va
n
ta
ge
s
M
o
n
it
o
ri
n
g
Si
d
e-
ef
fe
ct
s/
sa
fe
ty
is
su
es
/
d
is
ad
va
n
ta
ge
U
F
H
1
2
–
3
0
A
n
ti
-F
II
a
(t
h
ro
m
b
in
)
A
n
ti
-F
X
a
<
1
E
xt
ra
ct
io
n
fr
o
m
p
o
rc
in
e
in
te
st
in
al
m
u
co
sa
B
io
lo
gi
ca
lc
o
n
-
ta
m
in
at
io
n
In
tr
av
en
o
u
s
C
o
n
ti
n
u
o
u
s
in
fu
si
o
n
W
id
es
p
re
ad
av
ai
la
b
ili
ty
Lo
w
co
st
R
ev
er
si
b
le
Fr
eq
u
en
t
m
o
n
it
o
ri
n
g
d
u
e
to
va
ri
ab
le
d
o
se
re
sp
o
n
se
A
P
T
T
A
n
ti
-X
a
∼
3
0
%
o
ft
h
e
d
o
se
is
th
er
ap
eu
ti
c
B
le
ed
in
g
H
ep
ar
in
-i
n
d
u
ce
d
T
h
ro
m
b
o
cy
to
p
en
ia
(H
IT
)
O
st
eo
p
o
ro
si
s
H
yp
o
al
d
o
st
er
o
n
is
m
H
ep
ar
in
-i
n
d
u
ce
d
sk
in
n
ec
ro
si
s
LM
W
H
3
.5
–
6
A
n
ti
-F
X
a
4
–
5
D
ep
o
ly
m
er
iz
at
io
n
o
f
U
F
H
B
io
lo
gi
ca
lc
o
n
-
ta
m
in
at
io
n
Su
b
cu
ta
n
eo
u
s
O
n
ce
/t
w
ic
e
d
ai
ly
B
io
av
ai
la
b
ili
ty
Le
ss
fr
eq
u
en
t
m
o
n
it
o
ri
n
g
A
n
ti
-X
a
as
sa
y
A
P
T
T
Fu
n
ct
io
n
al
ir
re
ve
rs
ib
ili
ty
B
le
ed
in
g
U
F
H
as
st
ar
ti
n
g
m
at
er
ia
l
U
LM
W
H
1
.7
A
n
ti
-F
X
a
1
7
–
2
1
C
h
em
ic
al
sy
n
th
es
is
N
o
n
e
Su
b
cu
ta
n
eo
u
s
O
n
ce
d
ai
ly
B
io
av
ai
la
b
ili
ty
N
o
t
re
q
u
ir
ed
ex
ce
p
t
in
sp
ec
if
ic
p
o
p
u
la
ti
o
n
s
(e
.g
.,
ch
ild
re
n
)
Fu
n
ct
io
n
al
ir
re
ve
rs
ib
ili
ty
N
ot
es
:A
P
T
T,
ac
ti
va
te
d
p
ar
ti
al
th
ro
m
b
o
p
la
st
in
ti
m
e;
F
II
a,
T
h
ro
m
b
in
;F
X
a,
F
ac
to
r
X
a;
LM
W
H
,l
o
w
m
o
le
cu
la
r
w
ei
gh
t
h
ep
ar
in
;M
W
,m
o
le
cu
la
r
w
ei
gh
t,
U
F
H
,U
n
fr
ac
ti
o
n
at
ed
h
ep
ar
in
;U
LM
W
H
,
u
lt
ra
-l
o
w
m
o
le
cu
la
r
w
ei
gh
t
h
ep
ar
in
(f
o
n
d
ap
ar
in
u
x)
.
4 NAHAIN ET AL.
F IGURE 1 Structures of themajor (A) andminor (B) disaccharide sequences in heparin
F IGURE 2 Structure of the unique pentasaccharide (DEFGH) sequence of heparin, also known as the antithrombin
binding domain (ABD)
changed slightly over time as the industry has transitioned from beef lung to porcine intestine as the primary source
tissue.20
Heparin is a highly sulfated polyanionic polysaccharide consisting of repeating disaccharide subunits of 1→4 linked
𝛼-D-glucosamine (GlcN) and a uronic acid, typically 90% 𝛼-L-iduronic acid (IdoA) and 10% 𝛽-D-glucuronic acid (GlcA).
Themost common structure occurring in heparin is the trisulfated disaccharide IdoA2S-GlcNS6S (Figure 1), however, a
number of structural variations exist, leading to the microheterogeneity of heparin.21 Different sulfation patterns are
unevenly distributed along the heparin chains, with highly charged sequencesmostly concentrated at the nonreducing
end and less charged sequences at the reducing end, with mixed sequences between these two regions.21 The propor-
tions of differently charged domains and the actual composition within these domains vary depending on the animal
and organ source and also on the extraction and purification procedures.22 For example, during manufacture of UFH
base-catalyzed displacement of sulfate from Ido2S and/or enrichment of 6-O-sulfated sequences via chromatographic
purification can occur at variable levels.22
Heparin exerts its anticoagulant effects primarily through its interaction with the serpin (serine protease inhibitor)
AT, bringing about a conformational change and thus allowing it to interact with the proteases FXa and FIIa. To induce
the conformational change in AT, an AT-binding domain (ABD) comprised of a specific pentasaccharide sequence con-
taining the 3-O-sulfated GlcN residuemust be present (DEFGH, Figure 2). The pentasaccharide ABD stimulates exclu-
sively the AT-mediated inactivation of FXa, whereas longer heparin fragments (at least 14–16 saccharides long) with a
thrombin-binding domain (TBD) situated to the nonreducing end of the ABD, are required for inhibition of thrombin.
TheminimumMWof a heparin chainwith anti-IIa activity is thus approximately 5 kDa.23 The combination of ABDwith
extra chain length to include a TBD has been termed the “C-region”.24 Current heparin profilingmethods such as NMR
spectroscopy can provide an estimate of the amount of ABD content but not of the C-region.25 The variability in the
amount of ABD/C-region combined with the variation inMW leads to significant variability in bioavailability and anti-
coagulant effect for UFH. The anticoagulant activity of UFH strongly depends on the level of sulfation along with the
amount of ABD pentasaccharide sequences.
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F IGURE 3 Structures of fondaparinux (1) and idraparinux (2). R1 = SO3Na, R2 =Me
LMWHs are manufactured from UFH, using a variety of physical, chemical or enzymatic cleavage techniques.20,26
The defining characteristic of all LMWH products is that 60 wt% or more must have MW below 8 kDa.27 LMWHs
produced by different depolymerization processes result in unique structural alterations to the cleaved heparin
chains.28 These structural differences give rise to differences in their in vitro and pharmacokinetic/pharmacodynamic
properties.29
The fully synthetic methyl glycoside derivative of the ABD pentasaccharide is now marketed as the drug fonda-
parinux (1, Figure 3) following many years of development led by van Boeckel, Petitou, and co-workers.30,31 Their
earlier efforts resulted in a synthetic pentasaccharide with a low overall yield following complex synthetic proce-
dures taking 60 steps. Following the introduction of the methyl glycoside at the anomeric center of the H unit,30
the resultant pentasaccharide exhibited similar anticoagulant activity with additional advantages such as improved
yield and a longer half-life (17 hr). This preparation was then registered as drug in the United States and Europe
under the trade nameArixtra R© .32 Subsequently, the same group developed a fullyO-sulfated andO-methylated (non-
glycosaminoglycan) pentasaccharide known as idraparinux (2, Figure 3), which is an analogue of fondaparinux.33 This
pentasaccharide displayed some advantages over fondaparinux, such as ease of synthesis, improved anticoagulant
activity, and a longer half-life (120 hr).
To inhibit coagulation, the serine protease inhibitor AT belonging to the serpin family, plays the central role. How-
ever, under physiological conditions, as a stand-alone inhibitor it is not sufficiently potent.34 UFHaccelerates the activ-
ity of AT several thousandfold. The anticoagulant activity of UFH was first discovered early in the 20th century, and
since 1937 it has been in use in the clinic.35 This long chain polysaccharide exhibits its effects in two ways. First, it
accelerates the inhibitory activity of AT on FVIIa, FIXa, FXa, FXIa, FXIIa, and FIIa via a conformational change of AT
after binding; this is known as an allosteric mechanism (Figure 4).36–38 Second, heparin directly binds thrombin via
electrostatic interactions, and reduces thrombin's activity by forming a bridge between thrombin and AT known as the
ternary complex.39–45 Sequential investigations by different groups have shown that to increase the inhibitory effect
of AT on FIXa and FXa, a unique pentasaccharide sequence is needed which can bind with AT.46,47 Moreover, to accel-
erate the anti-IIa activity following the ternary complex, an additional 13 monosaccharide units must be present with
that pentasaccharide.48
Only one-third of the UFHmolecules display anticoagulant activity through their interaction with AT.40,49–52 How-
ever, the anticoagulant activity of heparin strongly depends on the presence of N- and O-sulfates.53,54 The absence
of O-sulfate groups on the pentasaccharide (DEFGH) dramatically reduces anticoagulant activity. In addition, esteri-
fication of the carboxyl group of the uronic acids diminishes the anticoagulant activity.55–57 Although the bulk of the
literature indicates that DEFGH is the main active sequence of UFH to exert anticoagulant activity, some studies have
indicated that tetra or hexasaccharides also have anticoagulant activity.50,58
6 NAHAIN ET AL.
F IGURE 4 (A) antithrombin; (B) thrombin; (C) long chain heparin; (D) binding of heparin pentasaccharide with the
antithrombin; and (E) formation of ternary complex of heparin with thrombin and antithrombin. HBD: heparin binding
domain; ABD: antithrombin binding domain; TBD: thrombin binding domain
4 HEPARIN MIMETICS
Different strategies havebeenexplored to prepare heparinmimetics, such as the synthesis of heparin-relatedoligosac-
charides and their derivatives, the sulfonation of natural polysaccharides, for example, chitosan and hyaluronic acid
(HA); the synthesis of noncarbohydrate sulfated polymers; conjugation of sulfated oligosaccharides to synthetic poly-
mers; and the isolation of sulfated polysaccharides from different natural sources (see Table 2 and below). The key
structural feature behind all the above strategies is the presence of sulfo groups on a suitable scaffold. Interestingly,
there have also been some reports of small sulfated molecules as potential anticoagulants; while some nonsulfated
anionic compounds have also been shown to have anticoagulant properties.
4.1 Synthetic heparin oligosaccharide derivatives
A series of studies to develop ULMWH/heparin oligosaccharides by chemoenzymetic methods has been reported
by the Liu group.59–61 Recently two synthetic sulfated oligosaccharides (3 and 4, Figure 5) consisting of the ABD
of porcine and bovine heparin, respectively, were developed using a GlcA-anMan disaccharide (R in Figure 5) as the
starting material which was selected because it could be elongated by glycosyl transferases.59 These two oligosaccha-
rides were found to exhibit excellent anticoagulant activities with comparable pharmacokinetic properties to 1. Liu
and co-workers also generated a library of size defined N-sulfo-oligosaccharides using the disaccharide GlcA-anMan
as the starting material which was elongated by two bacterial glycosyltransferases.60 After C5-epimerization and O-
sulfonations, oligosaccharides were produced consisting of ABD and TBD connected via a linker domain (consisting
of repeating disaccharides of –GlcNAc-GlcA-). This is the first report of the preparation of heparin oligosaccharides
having up to 21 saccharide residues via chemoenzymatic synthesis. All the oligosaccharides displayed both anti-Xa
and anti-IIa activities and showed low binding to PF4, suggesting they would be less likely to cause heparin-induced
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F IGURE 5 Structures of the synthetic sulfated oligosaccharides consisting of theABDof porcine (3) and bovine hep-
arin (4)
F IGURE 6 Structures of synthetic LMWHs
thrombocytopenia. Additionally, this study concluded that a minimum of 19 saccharide residues is required for the
anti-IIa activity of themolecule. Although these oligosaccharides displayed strong anticoagulant activities, the synthe-
sis took 14 days and ultimately the oligosaccharides were structurally heterogeneous. To minimize this lengthy proce-
dure, a one-pot chemoenzymatic synthesis of LMWHwith anarrowpolydispersitywasdeveloped,whichwasnamedde
novo LMWH,61 using a tetrasaccharide primerwhich could be obtained in only 2 days. The in vitro and the ex vivo anti-
coagulation assays indicated higher potency of the de novo LMWH compared with the commercially available LMWH
enoxaparin.
Subsequently, five LMWHs (5a–c and 6a,b, Figure 6) ranging from hexasaccharide to dodecasaccharide were
synthesized from commercially available monosaccharide 1-O-(p-nitrophenyl)-glucuronide as the starting mate-
rial, instead of the GlcA-anMan disaccharide.14 Each oligosaccharide consisted of the ABD from porcine (5a–c)
or bovine (6a, b) heparin. Oligosaccharides 5a–c were constructed by changing the number of IdoA2S-GlcN6S
repeating units while the dodecasaccharide 6a differs from 6b by lack of one 3-O-sulfate group. The results from the
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F IGURE 7 Chemical structure of idrabiotaparinux (7).63 R1= SO3Na, R2=Me
anticoagulant assays demonstrated strong binding affinity toAT and anti-FXa activity from these five oligosaccharides.
The reversibility of the anticoagulation properties of these five oligosaccharides was evaluated by treatment with
protamine sulfate where the dodecasaccharide 6b displayed higher reversibility than the LMWH enoxaparin and
similar to UFH. Eight related hexasaccharides containing 2-O-sulfated glucuronic acid (GlcA2S) were also prepared by
chemoenzymatic synthesis using monosaccharide 1-O-(p-nitrophenyl)-glucuronide as the starting material.62 Three
hexasaccharides were subjected to AT binding affinity testing by affinity coelectrophoresis.62 This study revealed that
without the presence of 2-O-sulfated iduronic acid, the oligosaccharides are not able to bind to AT.
The development of idraparinux (2) was halted due to excessive bleeding complications and the very long half-life.63
To overcome these concerns, biotin was conjugated to C-2 of the nonreducing end saccharide unit of idraparinux to
give idrabiotaparinux (7, Figure 7) to allow for rapid neutralization with avidin.63 This compound showed the same
anticoagulant properties as idraparinux,63,64 however, its development was also discontinued.
From the study of the formation of the ternary complex of heparin with AT and thrombin, it was found that the
bridge between ABD and TBD does not interact with positively charged protein residues.65 This finding informed the
design of tailor-made glycoconjgugates such as 8 and 9 (Figure 8) with the full anticoagulant properties of heparin,
consisting of synthetic ABD and TBD domains linked through a molecular spacer. Initially, a nonglycosaminoglycan
ABD pentasaccharide (i.e., idraparinux) was connected via a molecular spacer to a persulfated maltotrioside as the
TBD.65,66 This study revealed that the anticoagulant activity was dependent on all three domains of the conjugate.
When the spacer length was short, the conjugates failed to form any ternary complex when both the ABD and TBD
were fixed. The optimum length spacer was found to be around 50 atoms long. It was subsequently found that a rigid
linker such as a neutral heptasaccharide such as in conjugate 9 increased the anticoagulant activity compared with
flexible ones. In addition, the charge density of the TBDwas found to regulate the anti-IIa activity.
Taking advantage of the availability of direct thrombin inhibitors, the same group also developed dual active
antithrombotic conjugates. A dual inhibitor Org39913 (10, Figure 9) which can inhibit the action of thrombin and FXa
throughATwasdevelopedby conjugating thedirect thrombin inhibitor𝛼-NAPAP [𝛼-N-(2-naphthalenesulfonyl)-glycyl-
D-4-aminophenylalanyl-piperidine] and an idraparinux pentasaccharide analogue.67 It was then optimized by decreas-
ing the number of sulfate groups, replacing the aromatic linker by 𝛾-aminobutyric acid and using a single enantiomer of
aNAPAPanalogue. The resultant conjugateOrg42675 (11, Figure9) exhibited similarAT-mediated anti-FXa activity to
1, a ten times longer half-life than the direct thrombin inhibitor on its own,68 and thrombin inhibitionwas enhanced 20
times comparedwith 10. Conjugation of a biotin tag toOrg42675 (also known as EP42675) resulted in EP217609 (12,
Figure 9), which could retain the activities of Org42675 and could be neutralized by avidin injection.68,69 In another
study, following a similar strategy, EP224283 (13) was developed consisting of idraparinux conjugated to the 𝛼IIb𝛽3
inhibitor tirofiban,70 in addition to biotin, producing a neutralizable conjugate with both anti-FXa and antiplatelet
activity. It is noteworthy that tirofiban on its own has a very short half-life and cannot be used for outpatients whereas
13 has amuch longer half-life due to the presence of the idraparinuxmoiety.
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F IGURE 8 Synthetic tailor-made glycoconjugates consisting ofABDandTBD through flexible (8) and rigid (9)molec-
ular spacers65,66
Recently, Oscarson and Desai generated an in silico library of 46,656 heparan sulfate hexasaccharides and found a
rare sequence consisting of consecutive GlcA2S residues which could selectively target heparin cofactor II (HCII),71
another serpin involved in the regulation of blood coagulation via inhibition of FIIa. They synthesized five unique
sequences including three containing at least oneGlcA2S residue (a residue rarely found in heparin). Of particular note
was the hexasaccharideHX3 (14, Figure 10), which inducedHCII activation nearly 250-fold, similar to AT activation by
1. Compound14, which contains two consecutiveGlcA2S residues, was a poor activator of AT (only fivefold), indicating
a high selectivity for HCII.
4.2 Polysulfated non-heparin oligosaccharides and derivatives
A series of synthetic polysulfated oligosaccharides, prepared by chemical sulfonation of various isolated oligosaccha-
rides, was tested for anticoagulant activity by determining the activated partial thromboplastin time (APTT).72 Anti-
coagulant activity was dependent on chain length, linkage, and nature of the constituent monosaccharides. One of the
most potent anticoagulants was PI-88 (15, Figure 11), amixture of polysulfatedmanno-oligosaccharides that has been
in clinical development as an anticancer agent,73,74 which was selected for further study. PI-88 was found to inhibit
blood coagulation via HCII-mediated thrombin inhibition and this activity could be neutralized by protamine sulfate.75
Raake et al. synthesized lowMWpolysulfated bis-lactobionic acid amides which possessed moderate to low anticoag-
ulant activity.76 One of the compounds, LW10082 (Aprosulate, 16) showed similar antithrombotic activity to LMWH
andwas initially found to stimulate HCII77; but inactivation of both FV, FX,78 and FVIII has also been reported. Abend-
schein and co-workers synthesized the highly sulfated tetrasaccharide derivativemaltodapoh (17) as an anticoagulant
consisting of twomaltose sugars linked through 1,3-diamino-2-propanol. Themechanism of anticoagulation bymalto-
dapoh is unclear but itwas thought that this compound does not inhibit thrombin function viaHCII.79 Desai et al. found
that the commercially available sucrose octasulfate (18) directly inhibits thrombin with high potency but low efficacy
after binding with exosite II of thrombin.80 Jairajpuri and co-workers synthesized trehalose octasulfate (19) as a dual
anticoagulant/antiplatelet agent but themechanism of action was not fully elucidated.81
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F IGURE 9 Structures of pentasaccharide conjugates Org39913 (10),67 Org42675 (11),68 EP217609 (12),69 and
EP224283 (13)70
NAHAIN ET AL. 13
F IGURE 10 Structure of synthetic hexasaccharide HX3 (14).71 R= SO3Na
F IGURE 11 Structures of the polysulfated PI-88 (15), bis-lactobionic acid amide LW10082 (16), maltodapoh (17),
sucrose octasulfate (18), and trehalose octasulfate (19). R= SO3Na
4.3 Sulfated non-heparin polysaccharides
4.3.1 Naturally occurring sulfated polysaccharides
BesidesUFH, various sulfatedpolysaccharides isolated fromawide rangeof natural sources such asCS,82–84 dermatan
sulfate (DS),83,85–87 sulfated galactan,88,89 and sulfated fucans88,90–96 have been shown to have anticoagulant activity.
These polysaccharides have been found to contain different degrees of sulfation at various positions in the saccharide
ring which have specific effects on the coagulation time and themechanism of action of each of themolecules.
Most early studies reported the ineffectiveness of both natural chondroitin-4-sulfate and chondroitin-6-sulfate
(known CSA and CSC, respectively) as anticoagulants due to the presence of only one sulfate group per disaccharide
unit,83,84 although one study did report that CSA had significant anticoagulant activity mediated through AT.82 Fuco-
sylated chondroitin sulfates (FCS), which contain heavily sulfated fucose residues at the O-3 position of the GlcA of
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CS, have been found to act as potent anticoagulants.97–109 The naturally occurring FCSs isolated from a sea cucum-
ber have been found to inhibit thrombin action via AT and HCII,100,107 and could inhibit FXa by forming the intrinsic
tenase complex.106 Depending on the position of the sulfate groups, Zhao et al. have shownATmediated anti-IIa activ-
ities by FCSs containing a higher proportion of 2,4-disulfated fucose; while 3,4-disulfated fucose functioned via a HCII
dependent pathway.100 Selective inhibition of FXawas displayed by the FCSs having at least 6–8 trisaccharide units.
DS (previously known as chondroitin sulfate B ), which contains L-IdoA instead of GlcA in the disaccharide unit, dis-
plays better anticoagulant activity although it contains a single sulfate group per disaccharide unit like CSA andCSC.83
DS accelerates the inhibitory action on thrombin of HCII but not of AT and it takes place in the vessel wall only after
vascular disruption.83,86,87,108–115 The variation in anticoagulant activity by DS has been reasoned to be due to the
structural heterogeneity caused by isolation from different sources such as porcine skin and intestinal mucosa and
bovine lung.83 For example, highly sulfated DS (25% w/w) from the skin of the ray Raja montagui exhibited 5–7-fold
higher anticoagulant activity due to containing twofold higher sulfate and uronic acid content compared with the DS
from porcine intestinal mucosa.87,108,116,117 Previously, the authors reported more potent anticoagulant activity from
the DS obtained from the skin of Raja radula via both HCII and to a lesser extent AT.118,119 In another study, variations
in anticoagulant activities of DS of similar structures isolated from different species of rays was observed.120 The DS
isolated from electric eel, Electrophorus electricus (L.), was shown to bemore potent compared with porcine DS.117 Lin-
hardt et al. have reported anti-Xa activity by the lowMWDS (4.2 kDa).121 Fernandez et al. reported the enhancement
of anticoagulant activity of activated protein C (APC) by DS.122
Both sulfated fucans and sulfated galactans, isolated from various species ofmarine organisms, have been reported
to possess anticoagulant activity.88,95 The methods of isolation of these anionic polysaccharides and their chemical
compositions have been summarized in recent reviews.95,96,123 Both AT- (30 times less potent than UFH) and HCII-
(similar potency to UFH and DS) mediated thrombin inhibition have been observed from the sulfated fucans isolated
from Pelvetia canaliculata.90,93 Similar mechanisms were observed by Mourao et al. from sulfated fucan isolated from
Laminaria cichorioides.124 This compound also displayed anti-Xa activity, however, to a lesser extent. On the other
hand, some sulfated fucans have been reported to inhibit FIIa function via HCII and not AT.91,92 It has been reported
that branched fucans directly inhibit FIIa, whereas both AT and HCII mediated activity have been reported for lin-
ear fucans.125 Similarly, galactan sulfate, isolated frommarine invertebrates, prolongs blood coagulation time through
inhibition of thrombin (similarly to UFH) via both HCII and AT.88,89
4.3.2 Chemical modification of naturally occurring polysaccharides
Polysaccharides with little or no sulfation and thus no anticoagulant activity can be converted into anticoagulants via
exhaustive chemical sulfonation. Sulfonation of the polysaccharides (such as chitosan, dextran and CSs) has generally
been carried out using sulfur trioxide pyridine (or triethylamine) complex, chlorosulfonic acid, or sulfuric acid/DCC
(N,N'-dicyclohexylcarbodiimide) as the sulfating agent.
As a source of polysaccharide for sulfonation, chitosan (deacetyl chitin) has been considered due to the presence of
𝛽-(1→ 4) linkages, linearity, and the presence of amino and acetamido groups (features in common with heparin).126
Chitosan does not have any anticoagulant effects but partial enzymatic depolymerization and sulfonation of the amino
and hydroxy functional groups and/or addition of carboxyl groups endows it with anticoagulant activity.126–142 Dif-
ferent methods of preparation of sulfated chitosan have been reviewed by Tamura et al. For sulfated chitosan, N-
sulfation at the C-2 position is required to inhibit blood coagulation.143–145 It has also been found that the 6-O-sulfate
group is critical for anticoagulant activity and the absence of sulfation at this position totally ablates the anticoagu-
lant activity.132,146 On the other hand, N-succinyl chitosan (20) and N,O-succinyl chitosan (21, Figure 12) without any
sulfate groups have been found to increase blood coagulation time.139 Ronghua et al. reported that the anticoagulant
activity of sulfated chitosan could be improvedbymodification of someof the amino groupswithN-acyl groups.134 Zou
and Khor have suggested that to act as an anticoagulant, sulfated chitosan must possess at least 36 consecutive sul-
fate groups along the polymer backbone.147 The reportedmechanisms of action of the various sulfated chitosans have
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F IGURE 12 Structures of theN-succinyl chitosan (20) andN,O-succinyl chitosan (21)
F IGURE 13 Structures of the sulfated galactomannan (22). R= SO3Na or H
varied across different studies, for example, indirect inhibition of thrombin via AT126,132,138,144,145,148,149 andHCII,138
or direct inhibition of thrombin and ATmediated FXa inhibition.138,149,150
HA, consisting of glucuronic acid 𝛽-(1→3) andN-acetylglucosamine 𝛽-(1→4) linkages, is a nonsulfated glycosamino-
glycan with no anticoagulant activity.151 Magnani et al. developed a range of sulfated HAs which displayed anticoagu-
lant activity dependent on the degree of sulfation.152 These compounds inhibited FIIa function via nonspecific electro-
static interactions and FXa via AT. This study concluded at least 3.5 sulfate groups per disaccharide unit are required
to enhance blood anticoagulation.152 Subsequently, HCII andATmediated thrombin inhibition by LMWandHMWsul-
fated HA, respectively, was reported.151
The sulfation of dextran, a branched glucan consisting of 𝛼-(1 → 6)-glycosidic linkages with 𝛼-(1 → 3)-linked
branches, has long been explored for the development of heparin mimetics with anticoagulant activity.153–157
Numerous studies have been reported to evaluate the anticoagulant activity of carboxymethyl benzylamide sulfonate
dextrans (CMDBS),113,158–165 and these have recently been reviewed by Maynard and co-workers.166 The CMDBS
derivativeswere found to inhibit thrombin activity via bothATandHCII.159,167–169 The related functionalized dextran-
methylcarboxylate benzylamide sulfate, which differs from CMDBS in the preparation and the degree of sulfation,165
displays higher anticoagulant activity than CMDBS.170 Besides sulfated dextrans, some other semisynthetic sulfated
𝛽-glucans have been found to act as anticoagulants which accelerate thrombin inhibition via HCII.171–173
Chemically sulfated galactomannan (22, Figure 13) with various degrees of sulfation (0.7–1.4 per saccharide) dis-
played moderate to higher anticoagulant activity than dextran sulfate and curdlan sulfate (a sulfated 𝛽(1→ 3)-linked
glucan).174 A study has shown that sulfated galactomannan could inhibit both FIIa and FXa, via a mechanism that is
thought to be different to that of UFH.175
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F IGURE 14 Structures of the synthetic sulfated alginate (23) and propylene glycol conjugated sulfated alginate (24)
Ronghua et al. expected that sulfation of alginate, consisting of 𝛽-D-mannuronic acid connected to 𝛼-L-guluronic
acid via 𝛽-(1→ 4) linkage, could provide a heparin-like structure (containing both sulfates and carboxylates).176 They
prepared sulfated alginate (SA) (23, Figure 14) using chlorosulfonic acid in formamide, and found that at 17 𝜇g/mL
the APTT was 226 sec whereas for UFH the APTT was 125sec at 10𝜇g/mL. Similarly, Zhao and co-workers prepared
SA of varying degrees of sulfation using sulfuric acid/N,N'-Dicyclohexylcarbodiimide (DCC) as the sulfating agent. The
SA also displayed excellent anticoagulant activity dependent on the degree of sulfation.177 Fan et al. reported that
SA prepared using trisulfated sodium amine as the sulfating agent inhibited the function of both FIIa and FXa.178 A
sulfated propylene glycol ester of lowMW alginate known as PSS (24, Figure 14) has been used as a drug in China for
more than 30 years for the treatment of CVDs. Lin et al. fractionated PSS and found that fractions with average MWs
of ∼52 or ∼26 kDa inhibited FIIa mediated by AT and HCII, while the lower MW fraction (∼12 kDa) weakly inhibited
FXamediated by AT.179,180
The naturally occurring CSs have poor anticoagulant activity. However, complete O-sulfonation of CSA results in
enhancedanticoagulant activity (similar to that of LMWH)by inhibiting the functionof FIIa viaHCII,181 while, complete
sulfonation of CSC (to produce “oversulfated CS” or OCS) increases prothrombin time more than 200-fold compared
with nativeCSCbut only one fourth the activity ofUFH.182 AlthoughOCShas anticoagulant activity, itwas responsible
for the deaths of more than 100 patients in 2007/8 when used to adulterate UFH, due to it causing severe anaphylac-
toid reactions10,14 Therefore the application of oversulfated CSs as anticoagulant drugs is unlikely.
Fully O-sulfated DS containing 4.0 sulfate groups per disaccharide unit showed FIIa inhibition via HCII.183 Acha-
ran sulfate, a glycosaminoglycan isolated from Achatina fulica, with a major disaccharide repeating unit of 𝛼-D-
GlcNAc(1→4)-𝛼-L-IdoA2S, shows no anticoagulant activity despite the structural similarity to heparin . However, after
chemical sulfonation the polysulfated acharan sulfate exhibited AT independent anti-IIa activity.184,185
4.3.3 Synthetic sulfated glycopolymers
The synthesis of sulfated glycopolymers, that is, mono- or oligosaccharides appended to a non-carbohydrate polymer
backbone, is another approach to prepare heparin mimetics possessing anticoagulant activity. The glycopolymers are
generally prepared by variousmethods of polymerization such as ring opening polymerization, free radical polymeriza-
tion, or ring-openingmetathesis polymerization (ROMP), utilizing as themonomers either sulfated saccharide units, or
nonsulfated saccharide units which are subsequently sulfonated after polymerization. The preparation of glycopoly-
mers and their biological activities have recently been reviewed byMiura et al., andMaynard and co-workers.166,186
The anticoagulant activity of a sulfated glycopolymer was first reported by Akashi et el.187 Poly(glucosyloxyethyl
methacrylate) was prepared by free radical polymerization using ammonium peroxodisulfate as an initiator. The gly-
copolymerwas then sulfonated using sulfur trioxide/DMF complex to give poly(glucosyloxyethyl methacrylate)sulfate
(25, Figure 15).187 The anticoagulant activity for 25, evaluated as the total human blood clotting time by the method
of Lee-White, was modest compared with UFH and DS, respectively. In subsequent studies, the mechanism of action
of 25 was determined to be acceleration of thrombin inhibition via formation of an insoluble fibrin complex with
fibrinogen188 and inhibition of thrombin function via HCII.187,189
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F IGURE 15 Structures of synthetic polysulfated glycopolymers with anticoagulant activity
Recently, Ayres and co-workers used a post-polymerization sulfonation strategy to prepare polyurea based
glycopolymers bearing pendant sulfated glucose (26), mannose (27), lactose (28), or glucosamine (29) residues
(Figure 15).190 The polymerswere synthesized by step-growth polymerization, using hexamethylene diisocyanate and
the corresponding glycosylated secondary diamine dimers, followed by sulfonation with SO3 pyridine complex. All the
sulfatedglycopolymersprolonged theAPTTby>300secat500𝜇g/mL,with26and29 found tobe themostpotent. The
mechanism of action for the thrombin inhibition was unclear but it was suggested that coagulation timewas increased
via both AT dependent and independent pathways.
The Chaikof group prepared lactose heptasulfate-based homopolymers 30 and acrylamide co-glycopolymers 31
via cyanoxyl mediated free-radical polymerization using sulfated monomers (Figure 15).191 Before polymerization,
acrylamide derivatized lactose heptasulfate was prepared as the monomer. The anticoagulant activity of 30 was
found to increase with increasing MW, but the high MW 30 (114,000) was still almost 20-fold less potent than
UFH. Interestingly, the low MW hetero-glycopolymer 31 (MW 9,300,) was more potent than homo-glycopolymer
30 which indicated that the acrylamide played an important role to increase coagulation time. Both of the gly-
copolymers acted as anticoagulants via selective sequestration of fibrinogen or potentiating the effect of other
proteases associated with coagulation, such as HCII. The lactose hepta-sulfated based homo- and copolymers
increased the coagulation time. However, the analogous trisulfated GlcNAc based homo- and copolymers failed
to show any anticoagulant activity, indicating that at least a sulfated disaccharide is required for anticoagulant
activity.
The glycopolymers 32 and 33 (Figure 16), consisting of the G (L-iduronic acid) andH (glucosamine) units of the ABD
pentasaccharide, were synthesized via ROMPbyHsieh-Wilson and co-workers.192 Although it is accepted that the full
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F IGURE 16 Structure of the synthetic glycopolymers 32 and 33, synthesized via ROMP by Hsieh-Wilson and co-
workers, consisting of the G (IdoA) and H (GlcN) unit of the ABD pentasaccharide
ABD pentasaccharide is required for AT-mediated anti-Xa activity, only the GH disaccharide of the ABD was utilized
as the monomer in the hope that a multivalent presentation on a polymeric scaffold would enhance binding affinity
to AT. Glycopolymer 32 also possesses an additional 3-O-sulfate on the H unit which has been shown to confer even
greater specificity for AT activation. Partially benzylated sulfated monomers were polymerized inMeOH/CH2Cl2 and
the resultant polymers were then deprotected by hydrogenolysis to give the final products. Glycopolymer 32, consist-
ing of 45 repeating tetrasulfated disaccharide units (MW∼ 43,000) was found to exhibit 100-foldmore potent anti-Xa
activity than UFH, LMWH, and Arixtra. However, the overall effect on APTT was less than for UFH (119 sec vs. > 180
sec at 150 𝜇g/mL). The FXa activity of 32 decreased significantly with decreasingMW. The single alteration in the sul-
fation pattern of theHunit to give the3-O-desulfated glycopolymer (33) totally abrogatedboth the anti-Xa and anti-IIa
activity.
4.3.4 Synthetic sulfated polymers
Considering the polyanionic behavior of UFH, particularly the presence of sulfate groups, a variety of anionic
homopolymers and copolymers have been prepared either from polymerization of anionic monomers or sulfonation
of hydroxyl groups after polymerization. The anticoagulant activity of homopolymers of water-insoluble sulfonated
styrene (SS), prepared by the sulfonation of polystyrene resin, was first reported by Fougnot and Jozefonvicz.193,194
Zhao and co-workers have developed a range of copolymers, consisting of SS (following post-polymerization sul-
fonation of styrene in the polymer) and other monomers, such as poly(sulfonated styrene-co-acrylic acid)-block-
poly(vinyl pyrrolidone)-block-poly(sulfonated styrene-co-acrylic acid) [poly(SS-co-AA)-b-PVP-b-P(SS-co-AA)] (34),195
poly(sulfonated styrene-co-methyl methacrylate) [poly(SS-co-MMA)] (35),196 and poly(sulfonated styrene-co-acrylic
acid-co-methyl methacrylate) [poly(SS-co-AA-co-MMA)] (36) by RAFT polymerization using a trithiocarbonate as the
RAFT agent (Figure 17).195,196 These polymers displayed APTT values of 300 sec to more than 400 sec at concen-
trations of 5.0 and 20.0mg/mL, respectively. Subsequently, poly(sodium 4-styrene sulfonate-co-sodiummethacrylate)
[poly(SSS-co-SMA)] (37) and poly(dopamine-g- sodium 4-styrene sulfonate-co-sodiummethacrylate) [poly(DA-g-SSS-
co-SMA)] (38) (Figure 17) were found to increase blood coagulation time at much lower concentrations than that of
34, 35 and 36.197 Recently, this group synthesized poly(SSS) (39) on carbon nanotubes by surface initiated atom trans-
fer polymerizationwhere bromide-functionalizedmultiwalled carbon nanotubeswere used as themacro initiators.198
The composite was found to inhibit the function of FXIIa, the first protease of the intrinsic pathway of the coagula-
tion cascade. Li et al. synthesized p(AA), p(SSS), and p(SSS-co-AA), and investigated their anticoagulant activity after
grafting onto poly(vinyl alcohol) p(VA).199 The PVA-g-p(SSS) was found to bemore efficient than PVA-g-p(AA), and the
p(SSS-co-AA) was themost potent anticoagulant among the three.
Williams and co-workers prepared polyurethaneswith varying ratios (30–80%) of propyl sulfonate groups to obtain
anticoagulants.200 The polymers displayed anticoagulant activity via thrombin inhibition, interference with fibrin
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F IGURE 17 Chemical structures of synthetic sulfated (noncarbohydrate) polymers
polymerization, and by forming a complex through interaction between the polymer, thrombin, fibrin, and the plasma
antiproteases. Ito et al. introduced sulfamate and carboxylate groups to their synthesized polyurethaneureas using
N-chlorosulfonyl isocyanate as the sulfonating agent.201 These polymers were also found to increase APTT with
increasing sulfate content.
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Sulfonation of polyethersulfone membranes, which was further blended with poly (acrylonitrile-co-acrylic acid-co-
vinyl pyrrolidone) [poly(AN-co-AA-co-VP)] to introduce carboxyl groups, was found to exhibit significant heparin-like
anticoagulant activity and to suppress platelet adhesion.202
Machovich et al. prepared sulfated poly(vinyl alcohol-co-acrylic acid) (40) and sulfated poly(viny alcohol) (41) hav-
ing different MWs (Figure 17).203 To exhibit effective anticoagulation, at least 20% charged groups were required.
The polymers were found to accelerate thrombin inhibition via AT, and inhibit the reaction between thrombin and
fibrinogen.203,204 Polymer 40was also found to inhibit both thrombin and plasmin activity.205
Tamada et al. prepared a series of sulfonated polyisoprenes (SPIPs) having various MW and different degrees of
sulfonation.206 The SPIPs were found to increase APTT values with increasing MW. Subsequently, it was found that
SPIPs interact strongly with fibrinogen and fibrin monomers by forming a complex that prevents the conversion of
fibrinogen to fibrin monomers and the polymerization of fibrin monomers.207
Min and co-workers prepared sulfonated poly(ethylene oxide) using propane sultone which displayed 14% antico-
agulant activity (based on APTT test) of UFH, and inhibited thrombin function rather than FXa.208
Joung et al. developed supramolecular structured sulfonated polyrotaxane, (a polyrotaxane is composed of
𝛼-cyclodextrin and polyethylene glycol (PEG)), which displayed anticoagulant activity by AT mediated thrombin
inhibition.209 Themost important feature of this polymer is its sliding and rotation of free 𝛼-cyclodextrins with anionic
groups which played an important role to enhance the anticoagulant activity.209,210
Besides linear synthetic sulfonated polymers, other shaped polymers such as hyperbranched or dendritic polymers
prepared from sulfonated monomers have been reported to act as anticoagulants. For example, hyper-branched sul-
fonated polyester nanoparticles inhibited both intrinsic and/or common pathways and thrombin activity or fibrin for-
mation from fibrinogen.211 Alban's group prepared tree-like structured dendritic polyglycerol sulfate whose anticoag-
ulant activity does not depend on theMWdue to the globular 3D structure.212
Several zwitterionic polymers have also been reported with anticoagulant activity, such as zwitterionic
poly(2-oxazoline), prepared using 1,3-propane sultone and 𝛽-propiolactone,213 and zwitterionic poly(sulfobetaine
methacrylate).214
4.3.5 Sulfated aromatic compounds/flavonoids and derivatives
Both synthetic and naturally occurring sulfated flavonoids and derivatives have been reported to possess anticoagu-
lant activity and this area has been recently reviewed by Pinto and co-workers.215 Of particular note are some tetrahy-
droisoquinolines which have been found to act as allosteric inhibitors of AT inhibition of FXa.216,217 Sulfated benzo-
furans have been found to possess more potent anti-Xa activity than FIIa activity. Cabrera and co-workers reported
the anticoagulant activity of trisulfated (42, Figure 18) and tetrasulfated quercetin (a flavonol) (43) which accelerated
thrombin inhibition via HCII while the fully sulfated quercetin persulfate accelerated FXa inhibition via AT.218 Sulfated
flavanols were found to exhibit ATmediated anti-Xa activity where the orientation of the sulfate groups influences the
potency, for example, (+)-catechin sulfate (44) was twofold more potent than (-)-catechin sulfate (45).219,220
Taking advantage of the activity of sulfated flavonoids and sulfated oligosaccharides, Pinto and co-workers devel-
oped a series of persulfated flavonoid-saccharide conjugates.221 The study found that 3-O-rutinosides (46 and 47)
directly inhibited FXa and 7-O-rutinosides (48 and 49) inhibited FXa via AT. Subsequently, trans-resveratrol 3-𝛽-D-
glucopyranoside persulfate (50) was prepared as a dual anticoagulant/antiplatelet agent.222
4.3.6 Nonsulfated anionic compounds as anticoagulants
In addition to the above mentioned sulfated compounds, the anticoagulant activity of heparin mimetic compounds
without any sulfate groups has also been reported. For example, the Desai group found that p(AA) (51, Figure 19)
increased the activation of AT which subsequently accelerated the inhibitory functions of FXa and thrombin depend-
ing on pH.223,224 At pH 6.0 poly(AA) was found to form a bridge between AT and FXa, however, this was completely
abolished at pH 7.4.
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F IGURE 18 Structures of sulfated flavonoids and derivatives with anticoagulant activity
F IGURE 19 Chemical structure of poly(acrylic acid) p(AA) (51)
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Both DNA and RNA aptamers have also been reported to inhibit blood coagulation by increasing the
inhibitory function of the coagulation factors. Bock and co-workers isolated single-stranded a 15mer-oligonucleotide
consensus sequence which inhibited thrombin-catalyzed fibrin-clot formation at nanomolar concentrations and dis-
played its anticoagulant activity via bindingwith exosite I ofAT.225,226 On theother hand, RNAaptamers have alsobeen
reported to increase blood coagulation time by acceleration of the inhibitory function of FXa, FVIIa, and FIXa.227,228
5 CONCLUSIONS
Since the discovery of UFH significant time and resources have been expended in the search for new anticoagulants
with similar properties to UFH but without its drawbacks. These ongoing research efforts, based on a mechanistic
understanding of the anticoagulant activity of UFH, have been largely directed toward mimicking the common pen-
tasaccharide sequence ABD, TBD, and the spacing between these two domains. This has resulted in the development
of commercially available LMWHs andULMWH (fondaparinux), all of which contain theABDofUFH, and are obtained
from the chemical and/or enzymatic modification of UFH or by total synthesis. More recently, and of particular note,
we have observed the development of tailor-made glycoconjugates with the full range of anticoagulant properties as
UFH but with improved pharmacodynamic profiles, as well as additional useful properties such as the ability to be
rapidly neutralized. Such conjugates offer an impressive array of biological properties that can be fine tuned to suit
the intended cardiovascular indication and hold much promise as anticoagulant therapeutics of the future, with some
having progressed to clinical trials. However, these glycoconjugates require long and complex syntheses for their man-
ufacture. Other, more simple strategies to heparinmimetics have thus been pursued, including themodification of nat-
urally occuring oligo- and polysaccharides and the development of heparin mimetic polymers derived from carbohy-
drate and non-carbohydrate monomers. The latter approaches have shown some promise with polymers identified
with significant anti-Xa activity, although most of these polymers are not as potent as UFH. In the future, we expect
thatmore structure-activity relationships will be unravelled and this may lead to the development of heparinmimetics
with improved properties, suitable for progression into the clinic.
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